CN114752529A - Lactobacillus plantarum HOM3201 strain, viable bacteria preparation thereof, preparation method and application - Google Patents
Lactobacillus plantarum HOM3201 strain, viable bacteria preparation thereof, preparation method and application Download PDFInfo
- Publication number
- CN114752529A CN114752529A CN202210472568.8A CN202210472568A CN114752529A CN 114752529 A CN114752529 A CN 114752529A CN 202210472568 A CN202210472568 A CN 202210472568A CN 114752529 A CN114752529 A CN 114752529A
- Authority
- CN
- China
- Prior art keywords
- strain
- hom3201
- lactobacillus plantarum
- preparation
- glucose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 89
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 89
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 89
- 241000894006 Bacteria Species 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 51
- 239000008103 glucose Substances 0.000 claims abstract description 51
- 210000004369 blood Anatomy 0.000 claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 37
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 20
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract description 16
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 241000700159 Rattus Species 0.000 claims description 27
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 208000018914 glucose metabolism disease Diseases 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000003223 protective agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 241001052560 Thallis Species 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000002068 microbial inoculum Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 2
- 230000010030 glucose lowering effect Effects 0.000 claims description 2
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 abstract description 6
- 150000002632 lipids Chemical class 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 238000002955 isolation Methods 0.000 description 13
- 239000006041 probiotic Substances 0.000 description 12
- 235000018291 probiotics Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000009630 liquid culture Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 101100490563 Caenorhabditis elegans adr-1 gene Proteins 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 8
- 235000021110 pickles Nutrition 0.000 description 8
- 230000000529 probiotic effect Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 7
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 7
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 7
- 108010028144 alpha-Glucosidases Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 6
- 241000186604 Lactobacillus reuteri Species 0.000 description 6
- 102100040918 Pro-glucagon Human genes 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 229940009289 bifidobacterium lactis Drugs 0.000 description 6
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 229940001882 lactobacillus reuteri Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 3
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 3
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 3
- 235000021109 kimchi Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000010802 sludge Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 241001462463 Lactobacillus plantarum ST-III Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 244000088415 Raphanus sativus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000015140 cultured milk Nutrition 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229960001305 cysteine hydrochloride Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- KEQXNNJHMWSZHK-UHFFFAOYSA-L 1,3,2,4$l^{2}-dioxathiaplumbetane 2,2-dioxide Chemical compound [Pb+2].[O-]S([O-])(=O)=O KEQXNNJHMWSZHK-UHFFFAOYSA-L 0.000 description 1
- 101150022075 ADR1 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- -1 DPPH free radical Chemical class 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000302909 Piper aduncum Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 235000010726 Vigna sinensis Nutrition 0.000 description 1
- 244000042314 Vigna unguiculata Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000000859 incretin Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000010699 lard oil Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum HOM3201 strain, a viable bacteria preparation containing the same, and a preparation method and application thereof. The preservation number of the lactobacillus plantarum HOM3201 strain is CGMCC No. 22700. The lactobacillus plantarum HOM3201 strain can obviously reduce the fasting blood glucose level of a rat with an insulin resistance glucose/lipid metabolic disorder model, increase the tolerance of an organism to glucose and reduce an insulin resistance index.
Description
Technical Field
The invention relates to the technical field of microorganisms, in particular to a Lactobacillus plantarum HOM3201 strain, a viable bacteria preparation containing the same, and a preparation method and application thereof.
Background
The World Health Organization (WHO) defines probiotics as active microorganisms that will benefit the host when consumed in sufficient quantities. Only strains that have proven to be beneficial to health through scientific research may be referred to as "probiotics". The core characteristics of probiotics are sufficient number, viable status and beneficial health functions. Lactobacillus plantarum (Lactobacillus plantarum) is a ubiquitous probiotic and is often isolated from fermented foods such as pickled vegetables and pickles and from human bodies. The lactobacillus plantarum has beneficial functions in improving intestinal barrier, diabetes, hypertension, obesity, infection resistance, mental diseases and the like.
The incidence of type 2 diabetes has increased year by year, with china being in the front of the world. The etiology and pathogenesis of type 2 diabetes are extremely complex, and at present, the relative or absolute deficiency of insulin in the body is caused mainly by the defects of insulin resistance and insulin secretion of peripheral tissues caused by genetic and environmental factors, so that the glucose uptake and utilization are reduced, and hyperglycemia is caused, thereby causing diabetes.
Current research directed at the regulation of blood glucose levels by probiotics is incomplete and systematic.
Disclosure of Invention
The invention provides a Lactobacillus plantarum HOM3201 strain, a viable bacteria preparation containing the same, a preparation method and application aiming at the problems of the prior art.
In order to achieve the above object, the present invention provides the following technical solutions:
on one hand, the invention provides a Lactobacillus plantarum HOM3201 strain, and the preservation number of the Lactobacillus plantarum HOM3201 strain is CGMCC No. 22700.
Preferably, the Lactobacillus plantarum HOM3201 strain comprises the 16srDNA sequence represented by SEQ ID NO: 1.
In another aspect, the present invention provides a live bacterial preparation comprising the lactobacillus plantarum HOM3201 strain according to the above.
Preferably, the live bacterial preparation comprises up to 4.0-8.0 x 10 11CFU/g viable bacteria.
Preferably, the live bacterial preparation further comprises an auxiliary material.
In a further aspect, the present invention provides a food or health product comprising a live bacterial formulation as described above.
In yet another aspect, the present invention provides the use of lactobacillus plantarum HOM3201 strain, as described above, for the preparation of a medicament for the auxiliary reduction of blood glucose.
The lactobacillus plantarum HOM3201 strain is used for reducing fasting blood glucose level of rats with insulin resistance glucose metabolism disorder/lipid metabolism disorder models, increasing the tolerance of organisms to glucose and reducing insulin resistance index.
Preferably, the lactobacillus plantarum HOM3201 strain is used for the treatment of diabetes.
In yet another aspect, the present invention provides a method of preparing a live bacterial formulation as described above, comprising the steps of: the lactobacillus plantarum HOM3201 strain of claim 1, expanded in an optimized liquid medium; collecting thalli; adding protective agent for resuspension, vacuum freeze drying, and pulverizing to obtain active microbial inoculum.
The invention has the following advantages:
(1) the lactobacillus plantarum HOM3201 can obviously reduce the fasting blood glucose level of a rat with an insulin resistance glucose/lipid metabolic disorder model, increase the tolerance of an organism to glucose and reduce an insulin resistance index.
(2) The lactobacillus plantarum disclosed by the invention has an excellent in-vitro probiotic function. The strain has excellent tolerance to artificial gastrointestinal fluids, antibacterial activity, antioxidant activity and the like.
(3) The active microbial inoculum has simple production process parameters, short period, high viable count and good stability, and can exert the effect for a long time.
Drawings
Fig. 1 shows a RAPD cluster analysis chart of lactobacillus plantarum HOM3201 strain constructed based on UPGMA method.
FIG. 2 shows the DPP-4 and alpha-glucosidase inhibition ratios of Lactobacillus plantarum HOM3201 strain of the invention.
FIG. 3 shows the effect of Lactobacillus plantarum HOM3201 strain of the invention on the glucose tolerance in rats, a model of insulin resistant glucose/lipid metabolism disorders.
Figure 4 shows a process flow diagram of the present invention.
Instructions for microbial preservation
The Lactobacillus plantarum HOM3201 strain is preserved in China general microbiological culture Collection center (CGMCC) 6.11.2021, with the preservation addresses as follows: the institute of microbiology, national academy of sciences No. 3, Xilu 1, Beijing, Chaoyang, Beijing; the preservation number is CGMCC No. 22700.
Detailed Description
The invention discloses a strain, characteristics and application, and can be realized by appropriately improving process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
Alpha-glucosidase inhibitors are oral hypoglycemic agents for type 2 diabetes, mainly acarbose and voglibose. The glucose-reducing mechanism of the alpha-glucosidase inhibitor is that the glucose-reducing mechanism slows down the rate of decomposing starch into glucose and reduces and delays the absorption of glucose by small intestine by inhibiting the alpha-glucosidase on intestinal mucosa, thereby reducing the blood sugar and having obvious effect on postprandial hyperglycemia. Alpha-glucosidase inhibitors do not stimulate insulin secretion and such drugs alone do not generally induce hypoglycemia and thus may help reduce fluctuations in blood glucose.
The lactobacillus plantarum HOM3201 can obviously reduce the fasting blood glucose level of a rat with an insulin resistant glucose/lipid metabolic disorder model, increase the tolerance of an organism to glucose and reduce an insulin resistant index. The blood sugar reducing mechanism is that lactobacillus plantarum HOM3201 grows and metabolizes to generate a DPP-4 inhibitor and an alpha-glucosidase inhibitor. The DPP-4 inhibitor stimulates the body to produce glucagon-like peptide-1 (GLP-1) and promotes insulin secretion by inhibiting DPP-4; the alpha-glucosidase inhibitor can slow down the speed of converting starch into glucose by inhibiting alpha-glucosidase, thereby achieving the purpose of reducing the glucose.
In order to make the technical problems to be solved, technical solutions adopted and advantages of the present invention clearer, the present invention will be described in detail with reference to the accompanying drawings and specific embodiments. The following examples are intended to illustrate the invention, but are not intended to limit the scope of the invention.
It should be noted that the experimental methods used in the present invention are all conventional methods unless otherwise specified.
The reagents and materials used in the present invention, unless otherwise specified, may be formulated by conventional methods or commercially available.
The kimchi used in the present invention:
the kimchi sample used in the present invention for isolating lactobacillus plantarum HOM3201 strain was from homemade handmade kimchi made by adults in all of the provinces of sichuan province. The preparation method comprises the following steps: cleaning vegetables (green radish, white radish, carrot, cabbage, cowpea, green pepper, etc.), cutting into small strips, and air drying; cleaning the pickle jar, airing, and then pouring a little high-degree white spirit for disinfection for later use; pouring clear water into an oil-free pot, adding cortex cinnamomi japonici, folium Pelargonii Graveolentis, fructus Zanthoxyli, fructus Anisi Stellati, crystal sugar, and rhizoma Zingiberis recens, boiling, cooling completely, pouring into a pickle jar, and adding wild pepper juice, Kaoliang spirit and vegetables. After the cover is closed, clean water is poured into the water tank to seal the jar. Fermenting in a shady and cool ventilating place for 10 days to obtain the pickle used in the invention.
The commercial strain of Lactobacillus plantarum used in the present invention was isolated from a commercial product containing the desired strain, as described in example 1.
Example 1 isolation and characterization of Lactobacillus plantarum HOM3201 Strain
(1) Lactobacillus plantarum strain screening medium formula
Modified MRS solid medium:
MRS culture medium (OXOID, CM1163), adding bromocresol green (Shanghai Biotech) 0.05g, and double distilled water 1L, and stirring well. Adjusting pH to 5.5, and sterilizing at 121 deg.C for 20 min.
(2) Separation and screening of Lactobacillus plantarum strains
Isolation and screening of HOM Lactobacillus plantarum Strain
1g of pickle is weighed and made into pickle juice by using 9mL of 0.9% physiological saline. Sucking 1mL of pickle juice, diluting the sample by a 10-fold dilution method with the dilution degree of 10-3-10-5. The diluted pickle juice is coated on the modified MRS plate and cultured for 72 hours in an anaerobic way at 35 ℃. Selecting single colony with wet and smooth surface, tidy edge, milky yellow or milky white colony and yellow periphery, streak culturing and purifying. Simultaneously, gram staining and microscopic examination are carried out to observe the colony morphology. Transferring the single colony to an MRS liquid culture medium for pure culture, preserving the seed by glycerol, separating 5 strains of lactobacillus plantarum, and respectively naming each strain as HOM3201, HOM3202, HOM3203, HOM3204 and HOM 3205.
b. Isolation and screening of commercial strains of Lactobacillus plantarum
The commercial strains of lactobacillus plantarum used in the present invention were isolated in commercial probiotic products, and the strain and product information was: lactobacillus plantarum Lp-115 (isolated from Yineng 300), Lactobacillus plantarum LP-ONLLY (isolated from Onli Children probiotic powder), Lactobacillus plantarum P-8 (isolated from Yixiyan Youyou), Lactobacillus plantarum CCFM8661 (isolated from Yixiyan and Mei) and Lactobacillus plantarum ST-III (isolated from Guangming Youyue fermented milk).
Method for isolation of commercial strains of Lactobacillus plantarum: 1g of powder containing commercial strain of Lactobacillus plantarum or fermented milk was weighed and resuspended in 9mL of 0.9% physiological saline. 1mL of sample is aspirated, diluted by 10-fold dilution, 2-3 suitable dilutions are selected, plated on modified MRS plates, and incubated at 35 ℃ for 72 h. Selecting single colony with wet and smooth surface, tidy edge, milky yellow or milky white colony and yellow periphery, streak culturing and purifying. Simultaneously, gram staining and microscopic examination are carried out to observe the colony morphology. Transferring the single colony to MRS liquid culture medium for pure culture, and preserving the strain with glycerol.
(3) Identification of HOM Lactobacillus plantarum Strain
Inoculating each strain into MRS liquid culture medium, culturing at 35 deg.C for 48h, extracting total bacterial DNA from each strain, performing 16S rDNA amplification, performing PCR amplification and agarose gel electrophoresis with universal primers 27F and 1492R, cutting, recovering gel, and sequencing (Shanghai' S engineering). Then, the above 5 strains HOM3201, HOM3202, HOM3203, HOM3204, HOM3205 were identified as Lactobacillus plantarum (Lactobacillus plantarum) by alignment in NCBI database using BLAST tool. Wherein 16S rDNA of HOM3201 is shown in SEQ ID NO: 1.
The sequence of the 16S rDNA of HOM3201 was determined as follows:
CATCATGATTTACATTTGAGTGAGTGGCGAACTGGTGAGTAACACGTGGGAAACCTGCCCAGAAGCGGGGGATAACACCTGGAAACAGATGCTAATACCGCATAACAACTTGGACCGCATGGTCCGAGTTTGAAAGATGGCTTCAGCTATCACTTTTGGATGGTCCCGCGGCGTATTAGCTAGATGGTGGGGTAACGGCTCACCATGGCAATGATACGTAGCCGACCTGAGAGGGTAATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGAAAGTCTGATGGAGCAACGCCGCGTGAGTGAAGAAGGGTTTCGGCTCGTAAAACTCTGTTGTTAAAGAAGAACATATCTGAGAGTAACTGTTCAGGTATTGACGGTATTTAACCAGAAAGCCACGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGTGGCAAGCGTTGTCCGGATTTATTGGGCGTAAAGCGAGCGCAGGCGGTTTTTTAAGTCTGATGTGAAAGCCTTCGGCTCAACCGAAGAAGTGCATCGGAAACTGGGAAACTTGAGTGCAGAAGAGGACAGTGGAACTCCATGTGTAGCGGTGAAATGCGTAGATATATGGAAGAACACCAGTGGCGAAGGCGGCTGTCTGGTCTGTAACTGACGCTGAGGCTCGAAAGTATGGGTAGCAAACAGGATTAGATACCCTGGTAGTCCATACCGTAAACGATGAATGCTAAGTGTTGGAGGGTTTCCGCCCTTCAGTGCTGCAGCTAACGCATTAAGCATTCCGCCTGGGGAGTACGGCCGCAAGGCTGAAACTCAAAGGAATTGACGGGGGCCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCTACGCGAAGAACCTTACCAGGTCTTGACATACTATGCAAATCTAAGAGATTAGACGTTCCCTTCGGGGACATGGATACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTTATTATCAGTTGCCAGCATTAAGTTGGGCACTCTGGTGAGACTGCCGGTGACAAACCGGAGGAAGGTGGGGATGACGTCAAATCATCATGCCCCTTATGACCTGGGCTACACACGTGCTACAATGGATGGTACAACGAGTTGCGAACTCGCGAGAGTAAGCTAATCTCTTAAAGCCATTCTCAGTTCGGATTGTAGGCTGCAACTCGCCTACATGAAGTCGGAATCGCTAGTAATCGCGGATCAGCATGCCGCGGTGAATACGTTCCCGGGCCTTGTACACACCGCCCGTCACACCATGAGAGTTTGTA
(4) analysis of molecular biological Properties of Lactobacillus plantarum Strain
The obtained strain of Lactobacillus plantarum HOM3201 was subjected to genotyping comparison studies with strains of Lactobacillus plantarum HOM3202, HOM3203, HOM3204 and HOM3205, as well as strains of the commercial strains Lactobacillus plantarum Lp-115, LP-ONLLY, P-8, CCFM8661 and ST-III, using a random amplified polymorphic DNA marker (RAPD) method, to determine the specificity of the obtained strains.
The genomic DNA of the strain was randomly amplified by using the primers OPA-02, OPA-18, OPL-07, OPL-16 and OPM-05 shown in Table 1 below. The amplification conditions were as follows: the template and primers were first kept at 95 ℃ for 5min, then lowered to 56 ℃ and the reaction mixture was added and amplified for 45 cycles as follows: denaturation at 94 ℃ for 1min, annealing at 30 ℃ for 1min and extension at 72 ℃ for 2 min.
TABLE 1
| Primer and method for producing the same | Sequence of | SEQ ID NO |
| OPA-02 | 5’-TGCCGAGCTG-3’ | 2 |
| OPA-18 | 5’-AGGTGACCGT-3’ | 3 |
| OPL-07 | 5’-AGGCGGGAAC-3’ | 4 |
| OPL-16 | 5’-AGGTTGCAGG-3’ | 5 |
| OPM-05 | 5’-GGGAACGTGT-3’ | 6 |
| 27F | 5’-AGTTTGATCMTGGCTCAG-3’ | 7 |
| 1492R | 5’-GGTTACCTTGTTACGACTT-3’ | 8 |
10 μ L of the PCR amplification product was detected by electrophoresis on a 2% agarose gel, followed by imaging on a gel imager. The RAPD profiles were cluster analyzed based on the UPGMA method using Bionumerics version 6.6 software. The results are shown in FIG. 1.
It is generally considered that strains having a similarity of more than 90% in phylogenetic trees have the possibility of being the same strain. The phylogenetic tree result of the experiment shows that the HOM3201 strain and other lactobacillus plantarum are not on one branch, the similarity is lower than 60%, and the significant difference exists. Thus, HOM3201 strain is genotype specific and unique as compared to HOM3202, HOM3203, HOM3204 and HOM3205 strains, as well as commercial strains Lp-115, LP-ONLLY, P-8, CCFM8661 and ST-III strains.
Example 2 gastrointestinal tract trafficability test
(1) Isolation and activation of strains
Three commercial strains of lactobacillus plantarum 299V (isolated from the Jarrow probiotic product, isolation procedure as in example 1 b. the isolation procedure for the commercial strain of lactobacillus plantarum) were selected for this experiment, as well as the strains of lactobacillus plantarum Lp-115 and lactobacillus plantarum ST-III isolated from the commercial probiotic product of example 1 as positive controls. The strains are respectively inoculated in MRS liquid culture medium, cultured for 24h at 37 ℃ and activated twice for standby.
(2) Preparation of artificial gastric juice
Taking 16.4mL of dilute hydrochloric acid and 10g of pepsin, adding about 800mL of water, shaking uniformly, adjusting the pH to 3.0, adding water to a constant volume of 1L, and filtering with a 0.22 mu m microporous membrane for later use.
(3) Preparation of artificial intestinal juice
Taking 6.8g of monopotassium phosphate, adding 500mL of water for dissolving, and adjusting the pH value to 6.8 by using 0.1mol/L sodium hydroxide solution; dissolving pancreatin 10g in water, mixing the two solutions, diluting to 1000mL, and filtering with 0.22 μm sterile filter membrane under sterile condition.
(4) Evaluation of the viability of a Strain in simulated Artificial gastrointestinal fluids
Taking 1mL of bacterial liquid of each strain, centrifuging, collecting thalli, adding into 10mL of artificial gastric juice, mixing uniformly, immediately counting viable bacteria number, and recording as T 0Placing in an incubator at 37 ℃ for 3h, and counting the number of viable bacteria and recording as T1. Centrifuging the sample, adding 10mL of artificial intestinal juice, mixing, culturing in an incubator at 37 ℃ for 3h, counting viable bacteria, and recording as T2. The survival rate is calculated by the following formula:
wherein, T0The number of viable bacteria of the test strain is CFU/mL for 0h before the pretreatment; t is1The number of viable bacteria of the test strain is treated by the artificial gastric juice for 3 hours; t is2The number of viable bacteria of the test strain is 3 hours after the test strain is treated by artificial gastric juice and artificial intestinal juice for 3 hours.
TABLE 2 survival rate of Lactobacillus plantarum in simulated artificial gastrointestinal fluids
*: significant difference compared with HOM3201 group (p <0.05)
**: significant difference compared with HOM3201 group (p <0.01)
As can be seen from table 2: after the lactobacillus plantarum HOM3201 strain is treated by simulated artificial gastric juice for 3 hours, the survival rate can reach 118.87%, and after the strain is continuously treated by simulated artificial intestinal juice for 3 hours, the survival rate can still reach 122.59%, which indicates that the lactobacillus plantarum HOM3201 strain has higher survival rate in the gastrointestinal tract.
Compared with the commercial strains of the lactobacillus plantarum 299V, LP-115 and ST-III, the lactobacillus plantarum HOM3201 has higher gastric juice resistance than the commercial strains of the lactobacillus plantarum 299V, LP-115 and ST-III, and has a remarkable or extremely remarkable difference.
Example 3 ability to repress common pathogenic bacteria test
(1) Pathogenic bacteria activation
Five pathogenic bacteria were selected in this experiment: coli (e.coli) ATCC8739, Salmonella typhimurium (Salmonella typhimurium) ATCC14028, Staphylococcus aureus (Staphylococcus aureus) ATCC6538, Pseudomonas aeruginosa (Pseudomonas aeruginosa) ATCC9027, Listeria monocytogenes (Listeria monocytogenes) ATCC 19111. These pathogenic strains were purchased from ATCC (American type culture Collection).
The pathogenic strains are respectively inoculated in nutrient agar culture medium and cultured for 12h at 37 ℃ under the condition of 200rpm oscillation. The indicator bacteria were adjusted to OD 0.1 with fresh medium for use.
(2) Activation of lactic acid bacteria strains
In this experiment, commercial strains of Lactobacillus plantarum 299V (isolation method same as examples 1 and 2), Lp-115 (isolation method same as example 1), ST-III (isolation method same as example 1), and Lactobacillus rhamnosus LGG (Lactobacillus rhamnosus) were selected as control strains, wherein the LGG strain was isolated from a Corylobacter powder product, and the isolation method was the same as example 1.
Respectively inoculating each strain into an MRS liquid culture medium, standing and culturing for 24 hours at 37 ℃, and activating twice to obtain strain fermentation liquor. Centrifuging at 11000rpm for 10min, collecting supernatant, and using MRS liquid culture medium as negative control. Note that: lactic acid bacteria are a general term for a large group, including lactobacilli and bifidobacteria.
(3) Preparation of plates
And (3) pouring the sterilized nutrient agar into a culture dish, adding 100 mu L of indicator bacterium liquid into a culture medium, uniformly mixing, and standing for solidification.
(4) Bacteriostatic test
The oxford cup was gently placed on the plate with sterile forceps, keeping a distance between the holes. Adding 150 μ L fermentation supernatant into the wells, respectively, placing in a refrigerator at 4 deg.C for diffusion for 12 hr, culturing in an incubator at 37 deg.C for 18 hr, observing and measuring the diameter of the inhibition zone.
TABLE 3 inhibitory Effect of Lactobacillus plantarum HOM3201 Strain on pathogenic bacteria
Note: "-" has no bacteriostatic activity, is less than 11 mm; the "+" 11mm is not more than the bacteriostatic circle and is less than 16 mm; the 16 mm-plus bacteriostatic circle is less than 23 mm; "+ + + +" is larger than or equal to 23mm
As can be seen from Table 3, Lactobacillus plantarum HOM3201 has inhibitory effects on 5 pathogenic bacteria. Compared with commercial strains of Lactobacillus plantarum 299V, Lp-115, ST-III strain and Lactobacillus rhamnosus LGG strain, the bacteriostatic ability is equivalent.
Example 4 antibiotic susceptibility test
The susceptibility test was performed according to the K-B agar method recommended by the American Committee for clinical standards (NCCLS) as follows:
(1) commercial strains Lactobacillus plantarum 299V, Lp-115, ST-III strain (same as example 3) were selected as control strains. The strains are respectively inoculated in MRS liquid culture medium, cultured for 24 hours at 37 ℃ and continuously activated for 3 generations.
(2) Taking 1mL of bacterial solution (1.5X 10)8CFU/mL), 15mL MRS solid culture medium is placed in a sterilization culture dish, mixed evenly, after the plate is solidified, a standard antibiotic drug sensitive paper sheet is attached, and after the plate is cultured for 24-48h at 37 ℃, the diameter of the inhibition zone is measured and recorded. The results are shown in Table 4, interpreted according to CLSI criteria.
TABLE 4 determination of the susceptibility of the lactic acid bacteria strains to 9 antibiotics
S (susceptable) indicates sensitivity; i (intermediate) means medium; r (resistance) represents drug resistance.
As can be seen from Table 4, HOM3201 strain exhibits resistance to vancomycin, gentamicin, streptomycin, kanamycin, and clindamycin, and is sensitive to chloramphenicol, tetracycline, ampicillin, and erythromycin. Compared with commercial strains of Lactobacillus plantarum 299V, Lp-115 and ST-III strain, the HOM3201 has no abnormal drug resistance.
Example 5 antioxidant Activity detection test
(1) Lactobacillus plantarum strain activation
Commercial strains of Lactobacillus plantarum Lp-115 and ST-III (isolation method same as example 1) were selected as positive strainsAnd (6) comparison. Inoculating each strain into MRS culture medium, standing at 37 deg.C for 24 hr, activating for 3 generations, centrifuging, and regulating the strain concentration to 3 × 1010CFU/mL for standby.
(2) Determination of antioxidant Activity
The indicators include total antioxidant capacity measurement (T-AOC), hydroxyl radical scavenging measurement (. OH), and DPPH radical scavenging measurement. The first two indexes are determined by using a kit purchased by Nanjing as a finished company according to an operation instruction. The principle of the colorimetric method adopted in the DPPH free radical scavenging test is that the free radical scavenger provides an electron to be paired with a lone pair of electrons of DPPH free radicals, so that the purple of the free radical scavenger is changed into yellow, the absorbance at the wavelength of 517nm is reduced, the change degree of the change degree is in a linear relation with the free radical scavenging degree, namely, the stronger the scavenging capability of the free radical scavenger is, the smaller the absorbance is. The results are shown in Table 5.
TABLE 5 in vitro determination of antioxidant Activity of Lactobacillus plantarum Strain
*: significant difference compared with HOM3201 group (p <0.05)
**: compared with the HOM3201 group, the difference is significant (p <0.01)
As can be seen from Table 5, Lactobacillus plantarum HOM3201 strain is prominent in terms of total antioxidant capacity, hydroxyl radical scavenging, DPPH radical scavenging. In terms of T-AOC, compared with the Lp-115 strain, the HOM3201 strain is excellent in performance and has very significant difference; there was no significant difference between the three groups in hydroxyl radical scavenging; compared with the Lp-115 strain, the HOM3201 strain has higher clearance rate and significant difference in DPPH free radical clearance; compared with ST-III strain, there is no obvious difference.
Example 6 preparation of active powder of Lactobacillus plantarum HOM3201 Strain
(1) Cultivation of strains
Lactobacillus plantarum HOM3201 strain is inoculated in MRS liquid culture medium, cultured for 24 hours at 37 ℃, and activated for 2 generations. Inoculating into fermentation medium (shown in Table 6), and culturing at 37 deg.C to obtain viable bacteria count of 2 × 1010CFU/mL or above.
TABLE 6 fermentation Medium formulation
(2) Preparation of freeze-drying protective agent
The protective agent containing 100g/L of skimmed milk powder, 50g/L of trehalose, 3g/L of vitamin C and 5g/L L-sodium glutamate is prepared by mixing sterile water and protective agent raw materials.
(3) Freeze drying
Centrifuging fermented bacteria liquid of Lactobacillus plantarum HOM3201 strain to collect bacterial sludge, washing bacterial sludge with 0.9% sterile normal saline, mixing bacterial sludge with the protective agent to make bacterial liquid concentration reach 1010Freeze drying in freeze dryer, pulverizing the fungus cake with fine grinder to obtain freeze dried fungus powder with viable count higher than 6.0 × 1011CFU/g。
Example 7 in vitro hypoglycemic efficacy and mechanism exploration of Lactobacillus plantarum HOM3201 Strain
(1) Configuration improved version MRS liquid medium
MRS culture medium (OXOID), adding 0.05% L-cysteine hydrochloride based on the finished product culture medium, stirring, and sterilizing at 121 deg.C for 20 min.
(2) Strain activation and sample treatment
Commercial strains of Lactobacillus plantarum 299V, Lp-115, ST-III (isolation procedure as in example 1), and Lactobacillus reuteri ADR1 were selected as positive controls, and the ADR-1 strain was isolated from Saccharopol products as in example 1.
Inoculating each strain into a fresh improved MRS liquid culture medium according to the inoculation amount of 1%, standing at 37 ℃ for anaerobic culture for 24h, and activating for 3 generations. Centrifuging the bacterial liquid at 8000rpm for 10min, and buffering with phosphateThe solution (PBS) was washed three times. Adjusting viable bacteria count to 4 × 1010CFU/mL, anaerobic culture for 8h, 8000rpm centrifugation for 10min, and supernatant fluid for use.
(3) DPP-4 inhibitory and alpha-glucosidase inhibitory screens
The in vitro screening of the hypoglycemic function is carried out by adopting a DPP-4 inhibitor screening kit (Abnova # KA1311) and an alpha-glucosidase inhibitor screening kit (Biovision # K938). The inhibition rate of the lactic acid bacteria sample on the above two enzymes was calculated (the results are shown in FIG. 2).
TABLE 7 DPP-4 and alpha-glucosidase inhibition ratios of the respective strains
*: significant difference compared with HOM3201 group (p <0.05)
As can be seen from Table 7, HOM3201 strain has a high inhibition rate on DPP-4 and alpha-glucosidase. In the DPP-4 inhibition rate inhibition assay, the HOM3201 strain group is higher than other groups, and the HOM3201 group has a significant difference (P <0.05) compared with ADR-1 and 299V strain groups. In the alpha-glucosidase inhibition assay, the HOM3201 strain group was lower than the ADR-1 group, but all higher than the other groups. Clinical literature studies have shown that Lactobacillus reuteri ADR-1 strain has blood glucose lowering effect. In summary, the HOM3201 strain can achieve the purpose of reducing blood glucose by producing high levels of DPP-4 inhibitor and alpha-glucosidase inhibitor (FIG. 2).
Example 8 Lactobacillus plantarum HOM3201 Strain stimulates NCI-H716 cells to secrete GLP-1
(1) Culture of NCI-H716 cells
NCI-H716 cells (purchased from cell banks of Chinese academy of sciences) were selected for this experiment and were grown in RPMI-1640(Gibco) medium containing 10% fetal bovine serum (Hyclone), 1% double antibody (penicillin and streptomycin, Hyclone), 37 ℃ with 5% CO2In an incubator。
(2) Culture of lactic acid bacteria strains
Three commercial strains (Lactobacillus reuteri ADR-1, Lactobacillus rhamnosus LGG and Bifidobacterium lactis CECT8145) were selected as positive controls. Bifidobacterium lactis CECT8145 strain was isolated from the donor powder of ADM.
The method for separating the bifidobacterium lactis CECT8145 comprises the following steps: weigh 1g of the bacterial powder and resuspend it in 9mL of 0.9% physiological saline. 1mL of sample was aspirated, diluted by 10-fold dilution, and 2-3 appropriate dilutions were plated on TOS (Merck,1.00043.0500) plates and incubated anaerobically at 37 ℃ for 72 h. Selecting single colony with wet and smooth surface, regular edge and milk white color, and streaking, culturing and purifying. Simultaneously, gram staining and microscopic examination are carried out to observe the colony morphology. Single colonies were transferred to MRS + 0.5% cysteine hydrochloride (Sigma,1161509) broth for pure culture and glycerol conservation.
Respectively inoculating lactobacillus plantarum HOM3201, lactobacillus reuteri ADR-1 and lactobacillus rhamnosus LGG into an MRS liquid culture medium, standing and culturing at 37 ℃ for 24h, and activating for 3 generations; inoculating Bifidobacterium lactis CECT8145 into MRS + 0.5% cysteine hydrochloride liquid culture medium, standing at 37 deg.C, and anaerobically culturing for 24 hr to activate for 3 generations; each bacterial solution was centrifuged at 8000rpm for 10min and washed three times with Krebs buffer (Sigma). Adjusting viable bacteria count to 1 × 1010CFU/mL, spare.
(3) GLP-1 endocrine assay
NCI-H716 cells were cultured at 1.5X 106Cell/well Density was seeded in matrigel coated 24-well plates (Corning) and added to endocrine differentiation media at 37 deg.C with 5% CO2The incubator (2) was cultured for 2 days to perform an endocrine differentiation experiment. The endocrine differentiation medium was dmem (gibco) medium containing 10% fetal bovine serum, 1% double antibody and high glucose.
After 2 days, DMEM medium was replaced with Krebs-Ringer buffer containing 1X 10 cells10CFU/mL probiotic strain, after 2h of culture, 8000rpm centrifugation for 10min, collecting supernatant. 50. mu.g/mL of phenylmethylsulfonyl fluoride (Roche) and 10. mu.g/mL of sitagliptin (Sigma) were added to the supernatant, and then GL was detected using ELISA kit (Raybiotech)Concentration of P-1.
TABLE 8 production of GLP-1 by NCI-H716 cells stimulated by each strain 
*: compared with the HOM3201 group, the gene has significant difference (P <0.05)
**: compared with the HOM3201 group, the difference is significant (P <0.01)
Three commercial strains (Lactobacillus reuteri ADR-1, Lactobacillus rhamnosus LGG and Bifidobacterium lactis CECT8145) were documented as having hypoglycemic relevant studies.
As can be seen from Table 8, the HOM3201 strain can stimulate NCI-H716 cells to secrete high-content GLP-1 at a concentration of 1890.21 + -158.38 pg/mL. Compared with Lactobacillus reuteri ADR-1, the HOM3201 strain has very significant difference (p < 0.01); compared with lactobacillus rhamnosus LGG and bifidobacterium lactis CECT8145, the HOM3201 strain has a significant difference (p < 0.05). The results show that the Lactobacillus plantarum HOM3201 strain has the efficacy of reducing blood sugar, and the blood sugar reducing mechanism is probably that high-content GLP-1 is produced by stimulating L cells in intestinal tracts.
Example 9 Lactobacillus plantarum HOM3201 Strain on insulin resistance induced by alloxan against glucose/lipid metabolism disorder model rat blood glucose Effect
(1) Selecting Beijing Huafukang Biotechnology corporation [ license number: 46 healthy SPF-grade SD male rats of 140g to 160g bred by SCXK- (Jing) 2019-: SYXK (Jing) 2017-. The experiment was carried out in two batches. Experiment a batch of 10 rats are subjected to an experiment for influencing the fasting blood glucose of normal rats; experiment two 36-batch fasting blood glucose experiment of rat model of alloxan induced insulin resistant glucose/lipid metabolism disorder; sugar tolerance test; serum triglyceride and total cholesterol tests; serum insulin test. The formula of the high-heat-energy feed comprises the following components: 52.6 percent of basic feed, 15 percent of cane sugar, 15 percent of yolk powder, 10 percent of lard oil, 5 percent of casein, 1.2 percent of cholesterol, 0.2 percent of sodium cholate, 0.6 percent of calcium bicarbonate and 0.4 percent of stone powder.
(2) Normal rat fasting blood glucose effect test: the ordinary feed is suitable for feeding for 3 days, is fasted for 4h, is taken from blood, is kept stand for 10min, is centrifuged at 3000r/min for 10min to separate serum, and is used for measuring the blood sugar value before (namely 0h) glucose is given by a biochemical analyzer, and the blood sugar values after 0.5 h and 2h are given to 2.5g/kg BW glucose and are used as the basic values of the batch of animals. Let normal control group (0 CFU/mouse) and HOM3201 group (5 × 10)10CFU/kg BW); each group of 5 rats was fasted for 4h at the end of the experiment, blood was taken from the angular venous plexus, fasting blood glucose values were measured using a biochemical analyzer, and the initial and end rat body weights were measured.
TABLE 9 Lactobacillus plantarum HOM3201 Strain Effect on body weight of Normal rats
As can be seen from Table 9, the body weights of normal rats before and after the experiment were compared between the two groups, and the difference was not significant (P > 0.05).
TABLE 10 Lactobacillus plantarum HOM3201 Strain effects on fasting plasma glucose in Normal rats
As can be seen from Table 10, the difference between the blood glucose levels before and after the experiment was not significant (P > 0.05).
(3) Alloxan-induced insulin resistance glucose/lipid metabolism disorder model rat fasting blood glucose test: a blank control group, a model group and an HOM3201 strain group are set, and each group contains 12 oldMouse, HOM3201 strain group gavage dose 5 x 10 10CFU/kg BW. The test substance is given to each animal by 0.5mL by adopting an intragastric administration method, and the physiological saline with the same volume is given to a blank control group and a model control group once a day. After each group was fed with basal feed for one week, the model control group and the HOM3201 strain group were replaced with high-calorie feed, and after each group was fed for three weeks, the model control group and the HOM3201 strain group were fasted for 24 hours, and alloxan 105mg/kg BW was administered by intraperitoneal injection, and the injection amount was 1mL/100g of body weight. The high calorie diet was continued for 5 days after injection. After the test is finished, rats in each group are fasted for 4 hours, blood is taken, and fasting blood glucose, glucose tolerance, serum insulin, total cholesterol and triglyceride levels are detected.
TABLE 11 rat body weight determination
As can be seen from Table 11, there was no significant difference in the body weight of the rats before and after the experiment in the model control group compared with the blank control group.
TABLE 12 glucose and glucose tolerance in rat glycolipid metabolic disorder model
**: compared with a blank control group, the composition has very significant difference (p <0.01)
TABLE 13 blood lipid and insulin resistance index of rat glycolipid metabolic disorder model
*: compared with a blank control group, the composition has significant difference (p <0.05)
As can be seen from tables 12 and 13, the blood glucose values of the model control group and the blank control group are very significantly different (P is less than 0.01) after 0h and 0.5h of glucose administration, and the blood glucose value of the model control group is more than or equal to 10mmol/L after 0.5h, which indicates that the model sugar metabolism disorder is established. Comparing the model control group with the blank control group, the serum total cholesterol rise is significantly different (P <0.05), and the establishment of the lipid metabolism disorder model is judged; compared with a blank control group, the insulin resistance index of the model control group is obviously reduced (P <0.05), and the success of the insulin resistance glucose/lipid metabolism disorder model is comprehensively judged.
TABLE 14 Effect of HOM3201 Strain on model rat body weight
TABLE 15 Effect of HOM3201 Strain on fasting plasma glucose in model rats
*: compared with a model control group, the compound has significant difference (p <0.05)
TABLE 16 Effect of HOM3201 Strain on glucose tolerance in model rats
*: compared with a model control group, the compound has significant difference (p <0.05)
As can be seen from tables 15 and 16, blood glucose values were significantly different between the two groups at 0h (p <0.05), and blood glucose values of the HOM3201 group were decreased but not significantly different at 0.5h (p > 0.05). At 2h, there was no significant difference between the two groups. This indicates that the HOM3201 probiotic bacteria can significantly reduce fasting blood glucose of model rats, reduce postprandial blood glucose value at 0.5h, and improve blood glucose tolerance (fig. 3).
TABLE 17 Effect of the HOM3201 Strain on serum cholesterol and triglycerides in model rats
As can be seen in Table 17, there was no significant difference in serum cholesterol and triglycerides in the HOM3201 strain group compared to the model control group (P > 0.05).
TABLE 18 Effect of HOM3201 on serum insulin resistance index in model rats
As can be seen from Table 18, the serum insulin resistance index of the HOM3201 strain group was decreased, but the difference was not significant (P >0.05), compared to the model control group.
FIG. 4 shows a process flow chart of the separation, screening, preparation of preparation, and hypoglycemic effect in vitro and animal experiments of Lactobacillus plantarum HOM3201 strain of the present invention.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and amendments can be made without departing from the principle of the present invention, and these modifications and amendments should also be considered as the protection scope of the present invention.
While embodiments of the invention have been described above, it is not intended to be limited to the details shown in the description and the examples, which are set forth, but are fully applicable to various fields of endeavor as are suited to the particular use contemplated, and further modifications will be readily apparent to those skilled in the art and it is intended, therefore, that the invention not be limited to the details shown and described herein without departing from the general concept as defined by the appended claims and their equivalents.
Claims (10)
1. A Lactobacillus plantarum HOM3201 strain is characterized in that the preservation number of the Lactobacillus plantarum HOM3201 strain is CGMCC No. 22700.
2. Lactobacillus plantarum HOM3201 strain according to claim 1, characterized in that Lactobacillus plantarum HOM3201 strain comprises the 16s rDNA sequence represented by SEQ ID No. 1.
3. A live bacterial preparation comprising lactobacillus plantarum HOM3201 strain according to claim 1.
4. A live bacterial preparation according to claim 3, characterized in that it comprises up to 4.0-8.0% yeast1011CFU/g viable bacteria.
5. A viable bacteria preparation according to claim 3 or 4, characterized in that it further comprises an auxiliary material.
6. A food or healthcare product comprising a live bacterial formulation according to any of claims 3 to 5.
7. Use of a Lactobacillus plantarum HOM3201 strain according to claim 1, for the preparation of a medicament for the adjuvant treatment of blood glucose lowering.
8. The use according to claim 7, wherein the Lactobacillus plantarum HOM3201 strain is used for lowering fasting blood glucose levels, increasing the body's tolerance to glucose and lowering the insulin resistance index in rats as model of insulin resistance glucose/lipid metabolism disorders.
9. The use as claimed in claim 7, characterized in that the Lactobacillus plantarum HOM3201 strain is used for the treatment of diabetes.
10. A method of preparing a live bacterial formulation according to any of claims 3 to 5 comprising the steps of:
the lactobacillus plantarum HOM3201 strain according to claim 1, was grown in an optimized liquid medium;
collecting thalli;
adding a protective agent for resuspension, carrying out vacuum freeze drying, and crushing to obtain the active microbial inoculum.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472568.8A CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
| KR1020230055044A KR20230154400A (en) | 2022-04-29 | 2023-04-26 | Lactobacillus plantarum hom3201 strain and its live bacterial preparation, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210472568.8A CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114752529A true CN114752529A (en) | 2022-07-15 |
| CN114752529B CN114752529B (en) | 2023-12-19 |
Family
ID=82333809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210472568.8A Active CN114752529B (en) | 2022-04-29 | 2022-04-29 | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20230154400A (en) |
| CN (1) | CN114752529B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350547A (en) * | 2021-12-17 | 2022-04-15 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN116200310A (en) * | 2023-03-17 | 2023-06-02 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for regulating intestinal hormone GLP-1 level and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN107502575A (en) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | One plant of Lactobacillus plantarum with the high inhibitory activity of α glucuroides |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN109810912A (en) * | 2017-11-21 | 2019-05-28 | 华大精准营养（深圳）科技有限公司 | One lactobacillus plantarum LH-511 and its application |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN113061543A (en) * | 2020-01-02 | 2021-07-02 | 北京科丽科技有限公司 | Lactobacillus plantarum and application thereof |
| CN114276953A (en) * | 2021-07-21 | 2022-04-05 | 重庆誉研生物科技有限公司 | Lactobacillus plantarum YE4 capable of inhibiting intestinal cell DPP-4 activity and application thereof in relieving diabetes |
| CN114317353A (en) * | 2021-12-30 | 2022-04-12 | 浙江大学 | Lactobacillus plantarum ZJUFYJ7 and application thereof |
-
2022
- 2022-04-29 CN CN202210472568.8A patent/CN114752529B/en active Active
-
2023
- 2023-04-26 KR KR1020230055044A patent/KR20230154400A/en not_active Application Discontinuation
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107475160A (en) * | 2017-09-20 | 2017-12-15 | 中国农业科学院农产品加工研究所 | Lactobacillus plantarum and its application with dual hypoglycemic target spot |
| CN107502575A (en) * | 2017-09-20 | 2017-12-22 | 中国农业科学院农产品加工研究所 | One plant of Lactobacillus plantarum with the high inhibitory activity of α glucuroides |
| CN109810912A (en) * | 2017-11-21 | 2019-05-28 | 华大精准营养（深圳）科技有限公司 | One lactobacillus plantarum LH-511 and its application |
| CN108085285A (en) * | 2018-01-25 | 2018-05-29 | 吉林省命之元生物科技有限公司 | One DM-50 plants of lactobacillus plantarum and its application |
| CN110964659A (en) * | 2019-08-02 | 2020-04-07 | 四川大学 | Lactobacillus plantarum with blood sugar reducing effect, screening method thereof, application medicament and food |
| CN113061543A (en) * | 2020-01-02 | 2021-07-02 | 北京科丽科技有限公司 | Lactobacillus plantarum and application thereof |
| KR20210088408A (en) * | 2020-01-02 | 2021-07-14 | 코리 베이징 컴퍼니 리미티드 | Lactobacillus Plantarum and uses thereof |
| CN114276953A (en) * | 2021-07-21 | 2022-04-05 | 重庆誉研生物科技有限公司 | Lactobacillus plantarum YE4 capable of inhibiting intestinal cell DPP-4 activity and application thereof in relieving diabetes |
| CN114317353A (en) * | 2021-12-30 | 2022-04-12 | 浙江大学 | Lactobacillus plantarum ZJUFYJ7 and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ZHU ZENG等: "Screening for potential novel probiotic Lactobacillus strains based on high dipeptidyl peptidase IV and α-glucosidase inhibitory activity", JOURNAL OF FUNCTIONAL FOODS, vol. 20, pages 486 - 495 * |
| 董杰等: "乳酸菌代谢物中二肽基肽酶 -4 抑制剂的分离纯化及鉴定", 食品科学, vol. 41, no. 8, pages 116 - 122 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114350547A (en) * | 2021-12-17 | 2022-04-15 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN114350547B (en) * | 2021-12-17 | 2023-05-16 | 四川省医学科学院·四川省人民医院 | Bifidobacterium lactis strain B-622 and application thereof in preparation of medicines for treating diabetes |
| CN116200310A (en) * | 2023-03-17 | 2023-06-02 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for regulating intestinal hormone GLP-1 level and application thereof |
| CN116200310B (en) * | 2023-03-17 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | Probiotic agent for regulating intestinal hormone GLP-1 level and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230154400A (en) | 2023-11-08 |
| CN114752529B (en) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108102959B (en) | Humanized lactobacillus plantarum ZY08 for reducing cholesterol and application thereof | |
| CN110317757B (en) | Lactobacillus plantarum HJ-S2 with cholesterol-reducing and selenium-rich effects and application thereof | |
| CN109810912B (en) | Lactobacillus plantarum LH-511 and application thereof | |
| CN114752529B (en) | Lactobacillus plantarum HOM3201 strain and viable bacteria preparation, preparation method and application thereof | |
| CN113061543B (en) | Lactobacillus plantarum and application thereof | |
| CN111849810B (en) | Lactobacillus ZJuuiss 03 for antagonizing helicobacter pylori and application thereof | |
| CN111925961B (en) | Lactobacillus plantarum Lp2 and application thereof | |
| CN110157645B (en) | Lactobacillus salivarius Y4 and application thereof | |
| CN112143680B (en) | Lactobacillus paracasei ZJUIDS05 with antioxidant effect and application thereof | |
| CN114634901B (en) | Lactobacillus casei LC16 for promoting bone health and culture method and application thereof | |
| CN116004456B (en) | Lactobacillus reuteri A21325 for inhibiting helicobacter pylori infection and application thereof | |
| CN112812999B (en) | Lactobacillus plantarum SLB01 with inhibition effect on enterobacter cloacae and derivative product and application thereof | |
| CN116396890B (en) | Lactobacillus plantarum ZJUIDS15 for preventing and treating colon cancer and application thereof | |
| CN117327608A (en) | Lactobacillus rhamnosus strain and application thereof | |
| CN116970539B (en) | Lactobacillus murine complex, composition and application thereof | |
| CN115466693B (en) | Stokes Bei Jisi Rumex bacillus CY2 strain and application thereof | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| CN113528383B (en) | Hypoglycemic lactobacillus ZJUIDS09 and application thereof | |
| WO2019174002A1 (en) | Pediococcus pentosaceus ccfm1012, food fermented thereby and use thereof in preparation of medicine for antagonizing campylobacter jejuni infection | |
| Jikang et al. | Characterization and in vitro properties of Lactobacillus plantarum and Leuconostoc mesenteroides for probiotic potential and nitrite degradation. | |
| CN113430153B (en) | Lactobacillus reuteri ZJuuds 09 for reducing blood pressure and application thereof | |
| CN112972505B (en) | Application of lactobacillus fermentum in preparation of food or medicine with triglyceride reducing function | |
| CN117327604A (en) | Live bacterial preparation containing lactobacillus rhamnosus strain and application thereof | |
| CN117323349A (en) | Composition comprising lactobacillus rhamnosus strain and use thereof | |
| TW201809263A (en) | Immunnomodulatory Lactobacillus plantarumand use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |